RU2011136694A - КОМПЛЕКС ПЕПТИДА-ИНГИБИТОРА TGF-β1 И ЦИКЛОДЕКСТРИНА ИЛИ ЕГО ПРОИЗВОДНОГО, ЭМУЛЬСИЯ ПЕПТИДА-ИНГИБИТОРА TGF-β1, ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ ВЫШЕУКАЗАННЫХ КОМПЛЕКСА И ЭМУЛЬСИИ, ПРОДУКТ, ПОЛУЧЕННЫЙ ВЫШЕУПОМЯНУТЫМИ СПОСОБАМИ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ И/ИЛИ СОСТОЯНИЯ, ОПОСРЕДОВАННОГО TGF-β1 - Google Patents
КОМПЛЕКС ПЕПТИДА-ИНГИБИТОРА TGF-β1 И ЦИКЛОДЕКСТРИНА ИЛИ ЕГО ПРОИЗВОДНОГО, ЭМУЛЬСИЯ ПЕПТИДА-ИНГИБИТОРА TGF-β1, ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ ВЫШЕУКАЗАННЫХ КОМПЛЕКСА И ЭМУЛЬСИИ, ПРОДУКТ, ПОЛУЧЕННЫЙ ВЫШЕУПОМЯНУТЫМИ СПОСОБАМИ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ И/ИЛИ СОСТОЯНИЯ, ОПОСРЕДОВАННОГО TGF-β1 Download PDFInfo
- Publication number
- RU2011136694A RU2011136694A RU2011136694/15A RU2011136694A RU2011136694A RU 2011136694 A RU2011136694 A RU 2011136694A RU 2011136694/15 A RU2011136694/15 A RU 2011136694/15A RU 2011136694 A RU2011136694 A RU 2011136694A RU 2011136694 A RU2011136694 A RU 2011136694A
- Authority
- RU
- Russia
- Prior art keywords
- tgf
- cyclodextrin
- peptide
- emulsion
- complex
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract 29
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 title claims abstract 29
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 title claims abstract 29
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 22
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract 18
- 239000000839 emulsion Substances 0.000 title claims abstract 16
- 239000003112 inhibitor Substances 0.000 title claims abstract 8
- 239000003814 drug Substances 0.000 title claims abstract 6
- 238000000034 method Methods 0.000 title claims 8
- 201000010099 disease Diseases 0.000 title claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 4
- 230000001404 mediated effect Effects 0.000 title claims 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract 6
- 229940008099 dimethicone Drugs 0.000 claims abstract 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims abstract 6
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract 6
- 229960004853 betadex Drugs 0.000 claims abstract 5
- 239000001116 FEMA 4028 Substances 0.000 claims abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims abstract 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims abstract 3
- 229940097362 cyclodextrins Drugs 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900319 | 2009-02-05 | ||
| ESP200900319 | 2009-02-05 | ||
| PCT/ES2010/070062 WO2010089443A2 (es) | 2009-02-05 | 2010-02-04 | FORMULACIONES FARMACÉUTICAS DE PÉPTIDOS INHIBIDORES DE TGF- β1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011136694A true RU2011136694A (ru) | 2013-03-10 |
Family
ID=42320987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011136694/15A RU2011136694A (ru) | 2009-02-05 | 2010-02-04 | КОМПЛЕКС ПЕПТИДА-ИНГИБИТОРА TGF-β1 И ЦИКЛОДЕКСТРИНА ИЛИ ЕГО ПРОИЗВОДНОГО, ЭМУЛЬСИЯ ПЕПТИДА-ИНГИБИТОРА TGF-β1, ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ ВЫШЕУКАЗАННЫХ КОМПЛЕКСА И ЭМУЛЬСИИ, ПРОДУКТ, ПОЛУЧЕННЫЙ ВЫШЕУПОМЯНУТЫМИ СПОСОБАМИ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ И/ИЛИ СОСТОЯНИЯ, ОПОСРЕДОВАННОГО TGF-β1 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110294734A1 (enExample) |
| EP (1) | EP2394666A2 (enExample) |
| JP (1) | JP2012516879A (enExample) |
| CN (1) | CN102307598A (enExample) |
| AU (1) | AU2010210033A1 (enExample) |
| BR (1) | BRPI1008815A2 (enExample) |
| CA (1) | CA2750559A1 (enExample) |
| MX (1) | MX2011008261A (enExample) |
| RU (1) | RU2011136694A (enExample) |
| WO (1) | WO2010089443A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012154567A2 (en) * | 2011-05-06 | 2012-11-15 | Albert Einstein College Of Medicine Of Yeshiva University | Human invasion signature for prognosis of metastatic risk |
| MX366336B (es) * | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| US9353149B2 (en) * | 2013-05-10 | 2016-05-31 | Southern Research Institute | Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| FI3227675T3 (fi) | 2014-12-03 | 2023-05-25 | Celgene Corp | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi |
| KR101841748B1 (ko) * | 2016-02-18 | 2018-05-08 | (주)케어젠 | 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
| WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
| CN110483648A (zh) * | 2019-08-27 | 2019-11-22 | 南京安吉生物科技有限公司 | 一种融合多肽及其应用 |
| KR102779666B1 (ko) * | 2020-12-23 | 2025-03-12 | 한국과학기술연구원 | TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5215520A (en) * | 1991-09-17 | 1993-06-01 | Centre Internationale De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Method for delivering an active substance topically or percutaneously |
| US6132739A (en) * | 1998-09-01 | 2000-10-17 | Amway Corporation | Makeup compositions and methods of making same |
| ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| ES2371026T3 (es) * | 2001-10-19 | 2011-12-26 | Atritech, Inc. | Dispositivo de oclusión ajustable en la orejuela auricular izquierda. |
| WO2003048323A2 (en) | 2001-12-03 | 2003-06-12 | Bristol-Myers Squibb Company | Polynucleotides and polypeptides associated with the development of rheumatoid arthritis |
| ITRM20020119A1 (it) * | 2002-03-05 | 2003-09-05 | Geymonat Spa | Composizioni contenenti plgf ad uso farmaceutico e cosmetico. |
| ES2304069B1 (es) | 2003-08-22 | 2009-08-12 | Proyecto De Biomedicina Cima, S.L. | Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1). |
| US7279503B1 (en) * | 2004-11-02 | 2007-10-09 | Siltech Llc | Water in oil emulsions |
| EP1974740A4 (en) * | 2005-10-24 | 2010-09-01 | Proyecto Biomedicina Cima Sl | USE OF TGF-BETA1 INHIBITORY PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT |
| US7582609B2 (en) * | 2006-03-01 | 2009-09-01 | Digna Biotech, S.L. | Method for the treatment of skin fibrosis and suitable compositions for such treatment |
| DE102006031500A1 (de) * | 2006-07-06 | 2008-04-17 | Henkel Kgaa | O/W-Emulsion |
| WO2008013928A2 (en) * | 2006-07-28 | 2008-01-31 | Biogen Idec Ma Inc. | Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor |
| EP2091516A2 (en) * | 2006-12-01 | 2009-08-26 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
-
2010
- 2010-02-04 CA CA2750559A patent/CA2750559A1/en not_active Abandoned
- 2010-02-04 MX MX2011008261A patent/MX2011008261A/es not_active Application Discontinuation
- 2010-02-04 US US13/147,145 patent/US20110294734A1/en not_active Abandoned
- 2010-02-04 EP EP10708231A patent/EP2394666A2/en not_active Withdrawn
- 2010-02-04 AU AU2010210033A patent/AU2010210033A1/en not_active Abandoned
- 2010-02-04 CN CN2010800067872A patent/CN102307598A/zh active Pending
- 2010-02-04 WO PCT/ES2010/070062 patent/WO2010089443A2/es not_active Ceased
- 2010-02-04 BR BRPI1008815-6A patent/BRPI1008815A2/pt not_active IP Right Cessation
- 2010-02-04 RU RU2011136694/15A patent/RU2011136694A/ru not_active Application Discontinuation
- 2010-02-04 JP JP2011548731A patent/JP2012516879A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011008261A (es) | 2011-09-01 |
| CN102307598A (zh) | 2012-01-04 |
| AU2010210033A1 (en) | 2011-08-04 |
| WO2010089443A3 (es) | 2010-10-21 |
| US20110294734A1 (en) | 2011-12-01 |
| BRPI1008815A2 (pt) | 2018-02-14 |
| CA2750559A1 (en) | 2010-08-12 |
| WO2010089443A2 (es) | 2010-08-12 |
| EP2394666A2 (en) | 2011-12-14 |
| JP2012516879A (ja) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011136694A (ru) | КОМПЛЕКС ПЕПТИДА-ИНГИБИТОРА TGF-β1 И ЦИКЛОДЕКСТРИНА ИЛИ ЕГО ПРОИЗВОДНОГО, ЭМУЛЬСИЯ ПЕПТИДА-ИНГИБИТОРА TGF-β1, ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ ВЫШЕУКАЗАННЫХ КОМПЛЕКСА И ЭМУЛЬСИИ, ПРОДУКТ, ПОЛУЧЕННЫЙ ВЫШЕУПОМЯНУТЫМИ СПОСОБАМИ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ И/ИЛИ СОСТОЯНИЯ, ОПОСРЕДОВАННОГО TGF-β1 | |
| DK168514B1 (da) | Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet | |
| CN101921347B (zh) | 透明质酸衍生物及含有其的药剂 | |
| JP2010530846A (ja) | 高温で安定なペプチド製剤 | |
| TW200831113A (en) | Pharmaceutical agent having long-lasting effect of treating arthritic disorders | |
| US11633376B2 (en) | Method for treating metastatic prostate cancer | |
| JP6280628B2 (ja) | 疼痛抑制用医薬組成物 | |
| CN114392228A (zh) | 呈现长期稳定性的褪黑素注射剂的持久制剂 | |
| JP2019537589A5 (enExample) | ||
| JP2023517535A (ja) | ウイルス感染に使用するための化合物 | |
| KR101306956B1 (ko) | 부추로부터 분리된 신규 화합물 및 그 화합물의 항바이러스제로서의 용도 | |
| JP2015218147A (ja) | リラナフタート含有外用医薬組成物 | |
| WO2011104625A1 (en) | Cyclopolysaccharide compositions | |
| KR100950428B1 (ko) | 바이러스 억제제로서 유용한 디아릴헵타노이드계 화합물 | |
| WO2011088431A1 (en) | Prophylactic and treatment for virus-induced disease | |
| CA3056222C (en) | A drug for the effective control of acute and/or chronic pain and a method for its administration | |
| JP7295273B2 (ja) | 少なくともアミトリプチリンを含む水性ゲルの形態の局所用医薬組成物 | |
| JP2022185071A (ja) | 関節疾患処置用組成物およびこれを含むキット | |
| KR101295010B1 (ko) | 검은 생강으로부터 분리된 신규 화합물 및 그 화합물의 항바이러스제로서의 용도 | |
| RU2612221C1 (ru) | Блокаторы вируса гриппа | |
| US20240156856A1 (en) | Novel applications of hyaluronic acid for treatment of pain and pruritis | |
| KR20080096829A (ko) | 정맥내 항바이러스 치료 | |
| CN103371987B (zh) | 漆酚化合物在制备抑制肾脏组织纤维化的药物中的用途 | |
| CN101797266A (zh) | 一种含有槲皮苷的药物组合物及用途 | |
| FR3058640A1 (fr) | Composes pour leur utilisation dans le traitement de la grippe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140820 |